A LOW-INTERVENTIONAL, PROSPECTIVE, MULTI-CENTER STUDY TO EVALUATE REAL-WORLD CLINICAL, BIOCHEMICAL AND PATIENT-REPORTED RESPONSES TO TOFACITINIB INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS IN SWITZERLAND
Latest Information Update: 04 Oct 2024
At a glance
- Drugs Tofacitinib (Primary)
- Indications Ulcerative colitis
- Focus Therapeutic Use
- Acronyms KIC-START
- Sponsors Pfizer
- 01 Oct 2024 Status changed from recruiting to discontinued. ( Study was terminated due to difficulty in enrolling targeted number of participants. There were no safety and/or efficacy concerns in the decision to stop enrollment.)
- 19 Mar 2024 Planned End Date changed from 20 Oct 2023 to 21 Oct 2024.
- 19 Mar 2024 Planned primary completion date changed from 20 Oct 2023 to 21 Oct 2024.